Organization (Hospital)
METHODIST LE BONHEUR HEALTHCARE
ClinicalTrials.gov lists METHODIST LE BONHEUR HEALTHCARE as lead sponsor of 21 trials, counting the companies grouped under it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section
20 sections measured, none recorded
This page covers METHODIST LE BONHEUR HEALTHCARE and 1 company with a profile grouped under it (a further 1 registry-linked record in the group have no profile): 21 lead-sponsored trials (0 its own, 21 in the grouped companies) and 3 legal-entity registrations (2 its own, 1 in the grouped companies).
Companies grouped under this page (1)
| Company | Country | Lead trials | Legal entities |
|---|---|---|---|
| Le Bonheur Children's Hospital | US | 21 | 1 |
Counts companies with a profile grouped under this one. A further 1 registry-linked record in this group have no company profile and are not listed.
Disease areas (4)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Emergencies | 1 |
| Head and Neck Neoplasms | 1 |
| Hemophilia A | 1 |
| Hemophilia B | 1 |
Latest dated events (2)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Biomarkers this organization publishes on (10)
Shown in this order: most publications first.
Showing 5 of 10 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, trials by start year as sponsor or collaborator, active development programs, approved assets, sponsor delivery record, journals published in, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarker capability evidence.